Table 2. Tumour response (WHO) (Miller et al, 1981) (ITT and PP populations).
|
BDC study
|
GBC study
|
|||
|---|---|---|---|---|
| ITT population Number (%) of evaluable patients (n=37) | PP population Number (%) of evaluable patients (n=34) | ITT population Number (%) of evaluable patients (n=35) | PP population Number (%) of evaluable patients (n=31) | |
| CR | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PR | 7 (19) | 7 (20) | 8 (23) | 8 (26) |
| NC | 20 (54) | 20 (59) | 16 (46) | 16 (52) |
| PD | 6 (16) | 6 (18) | 6 (17) | 6 (19) |
| Not assessable | 4 (11) | 1 (3) | 5 (14) | 1 (3) |
| Overall response (CR+PR) | 7 (19) | 7 (20) | 8 (23) | 8 (26) |
| Disease control (CR+PR+NC) | 27 (73) | 27 (79) | 24 (69) | 24 (77) |
Abbreviations: BDC=bile duct cancer; CR=complete response; GBC=gallbladder cancer; ITT population=intention-to-treat-population; NC=no change; PD=progressive disease; PR=partial response; PP population=per-protocol-population (both populations have been defined in the text; see ‘Statistical methods and analysis’ section).